2,271 press releases in English indexed under biotech & pharma.
NEW YORK, Sept. 28, 2026 -- Why: New York, N.Y., September 28, 2026. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the...
Evosep and Mass Dynamics partner to standardize proteomics workflows, combining automated sample prep, QC, and analytics for pharma.
NEW YORK, Sept. 28, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
Syracuse practice, part of U.S. Urology Partners, a General Atlantic company, will run a first proof of concept of FuseRx, with ACRO clinical pathways built in, at its radiation oncology program in Syracuse SYRACUSE, N.Y. and BOONE, N.C., Sept. 28, 2026 -- Fuse Oncology and...
SAN DIEGO, Sept. 28, 2026 -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Euretina Innovation Spotlight (EIS) being held on September 30, 2026, and Euretina being held on October 1-4, 2026, in Vienna, Austria.
NEW YORK, Sept. 28, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.
Statement from Kathy Crosby, CEO and President of Truth Initiative WASHINGTON, Sept. 28, 2026 -- Today, the U.S. Food and Drug Administration announced that it plans to evaluate changes to the framework for applications for new tobacco products like e-cigarettes and nicotine...
SOUTH SAN FRANCISCO, Calif., September 28, 2026--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today broke ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon, advancing plans announced in August to increase capacity for advanced drug delivery devices and to strengthen the company’s United States manufacturing capabilities. The event marks the start of construction for the 211,000-square-feet expansion, doubling the size of the existing si
STOCKHOLM, SWEDEN, Sept. 28 2026. – Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX) today announced that the U.S. Food and Drug Administration (FDA) has approved EMCITATE® (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan–Herndon–Dudley syndrome). EMCITATE is not recommended for the treatment of primary hypothyroidism. EMCITATE is the first FDA-approved treatment option for patients with MCT8 deficiency in the United States.
MIAMI, September 28, 2026--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve).
Group cites 12 deaths in five 2026 attacks and urges states to require psychiatric-drug toxicology in homicides and mass acts of senseless violence Group cites 12 deaths in five 2026 attacks and urges states to require psychiatric-drug toxicology in homicides and mass acts of senseless violence
BOSTON, September 28, 2026--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.